CTMX
Income statement / Annual
Last year (2023), CytomX Therapeutics, Inc.'s total revenue was $101.21 M,
an increase of 90.38% from the previous year.
In 2023, CytomX Therapeutics, Inc.'s net income was -$569,000.00.
See CytomX Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$101.21 M
|
$53.16 M
|
$69.57 M
|
$100.36 M
|
$57.49 M
|
$59.50 M
|
$71.62 M
|
$15.04 M
|
$7.71 M
|
$5.08 M
|
| Cost of Revenue |
$2.18 M |
$5.86 M |
$5.84 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$99.04 M |
$47.31 M |
$63.73 M |
$100.36 M |
$57.49 M |
$59.50 M |
$71.62 M |
$15.04 M |
$7.71 M |
$5.08 M |
| Gross Profit Ratio |
0.98 |
0.89 |
0.92 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$77.68 M
|
$111.65 M
|
$114.19 M
|
$112.94 M
|
$131.62 M
|
$103.87 M
|
$92.28 M
|
$54.76 M
|
$28.36 M
|
$28.30 M
|
| General & Administrative
Expenses |
$30.02 M
|
$42.85 M
|
$39.16 M
|
$36.03 M
|
$36.77 M
|
$33.51 M
|
$25.61 M
|
$19.87 M
|
$12.56 M
|
$6.54 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$30.02 M
|
$42.85 M
|
$39.16 M
|
$36.03 M
|
$36.77 M
|
$33.51 M
|
$25.61 M
|
$19.87 M
|
$12.56 M
|
$6.54 M
|
| Other Expenses |
$0.00 |
$340,000.00 |
-$83,000.00 |
-$27,000.00 |
-$135,000.00 |
-$68,000.00 |
-$27,000.00 |
-$69,000.00 |
-$1.74 M |
-$55,000.00 |
| Operating Expenses |
$107.70 M |
$154.50 M |
$153.35 M |
$148.97 M |
$168.38 M |
$137.38 M |
$117.88 M |
$74.63 M |
$40.92 M |
$34.84 M |
| Cost And Expenses |
$107.70 M |
$154.50 M |
$153.35 M |
$148.97 M |
$168.38 M |
$137.38 M |
$117.88 M |
$74.63 M |
$40.92 M |
$34.84 M |
| Interest Income |
$9.84 M |
$1.68 M |
$255,000.00 |
$1.84 M |
$8.37 M |
$7.64 M |
$2.67 M |
$2.43 M |
$1.32 M |
$7,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.69 M |
$1.73 M |
$487,000.00 |
| Depreciation &
Amortization |
$2.18 M
|
$5.86 M
|
$5.84 M
|
$5.46 M
|
$2.61 M
|
$1.88 M
|
$1.65 M
|
$1.73 M
|
$1.21 M
|
$783,000.00
|
| EBITDA |
-$4.31 M
|
-$98.89 M
|
-$113.34 M
|
-$77.97 M
|
-$138.88 M
|
-$75.99 M
|
-$41.97 M
|
-$57.85 M
|
-$32.43 M
|
-$29.03 M
|
| EBITDA Ratio |
-0.04 |
-1.91 |
-1.2 |
-0.46 |
-1.93 |
-1.28 |
-0.62 |
-3.69 |
-4.2 |
-5.72 |
| Operating Income Ratio
|
-0.06
|
-1.91
|
-1.2
|
-0.48
|
-1.93
|
-1.31
|
-0.65
|
-3.96
|
-4.31
|
-5.86
|
| Total Other
Income/Expenses Net |
$9.81 M
|
$2.02 M
|
$172,000.00
|
$1.81 M
|
$8.23 M
|
$7.57 M
|
$2.65 M
|
$667,000.00
|
-$2.16 M
|
-$535,000.00
|
| Income Before Tax |
$3.32 M |
-$99.32 M |
-$83.61 M |
-$46.80 M |
-$102.67 M |
-$70.30 M |
-$43.61 M |
-$58.92 M |
-$35.36 M |
-$30.30 M |
| Income Before Tax Ratio
|
0.03
|
-1.87
|
-1.2
|
-0.47
|
-1.79
|
-1.18
|
-0.61
|
-3.92
|
-4.59
|
-5.97
|
| Income Tax Expense |
$3.89 M |
-$2.02 M |
-$2.96 M |
-$13.91 M |
-$427,000.00 |
$14.30 M |
-$513,000.00 |
-$19,000.00 |
$10,000.00 |
$10,000.00 |
| Net Income |
-$569,000.00 |
-$97.30 M |
-$80.65 M |
-$32.89 M |
-$102.24 M |
-$84.60 M |
-$43.10 M |
-$58.90 M |
-$35.37 M |
-$30.31 M |
| Net Income Ratio |
-0.01 |
-1.83 |
-1.16 |
-0.33 |
-1.78 |
-1.42 |
-0.6 |
-3.92 |
-4.59 |
-5.97 |
| EPS |
-0.0077 |
-1.48 |
-1.26 |
-0.71 |
-2.26 |
-2.03 |
-1.16 |
-1.63 |
-4.12 |
-0.87 |
| EPS Diluted |
-0.0077 |
-1.48 |
-1.26 |
-0.71 |
-2.26 |
-2.03 |
-1.16 |
-1.63 |
-4.12 |
-0.87 |
| Weighted Average Shares
Out |
$73.81 M
|
$65.74 M
|
$64.15 M
|
$46.15 M
|
$45.34 M
|
$41.66 M
|
$37.17 M
|
$36.23 M
|
$8.60 M
|
$34.92 M
|
| Weighted Average Shares
Out Diluted |
$73.81 M
|
$65.74 M
|
$64.15 M
|
$46.15 M
|
$45.34 M
|
$41.66 M
|
$37.17 M
|
$36.23 M
|
$8.60 M
|
$34.92 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
